에서 실시간으로 운영 중이에요! 자세히 알아보기

Sight Sciences

SGHT

시가총액 US$4.56억

8.28 USD

-0.52

5.91%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

1일

-5.91%

5일

-6.76%

1개월

1.72%

3개월

59.23%

6개월

116.19%

연초 이후

10.7%

1년

140%

5년

-62.53%

10년

-75.28%

소개: Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.

직원 수: 186

건강관리 의료기기

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 28.6%

중립 64.3%

부정적 7.1%

Why Is Sight Sciences Stock Gaining Thursday?

Sight Sciences, Inc. (NASDAQ:SGHT) stock gained Thursday after H.C. Wainwright initiated coverage with a Buy rating and a $14 price forecast.

Why Is Sight Sciences Stock Gaining Thursday?

Sight Sciences: Signs Of Progress, But Plenty Of Work Remains

Sight Sciences is a cautious 'buy,' as recent reimbursement wins and product momentum support a positive outlook, offset by liquidity pressures and ongoing reimbursement and utilization challenges. SGHT's OMNI Ultra Surgical System launch and updated TearCare label provide incremental adoption tailwinds, but procedure costs/reimbursement and surgeon preference remain key hurdles. Q2 revenue grew 20% with strong dry eye business acceleration, improved gross margins, and reduced cash burn; Aetna coverage adds 25 million insured lives to the glaucoma business.

Sight Sciences: Signs Of Progress, But Plenty Of Work Remains

Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting

MENLO PARK, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, interventional technologies intended to transform eye care and improve patients' lives, today announced the commercial availability of the OMNI® Ultra Surgical System (OMNI Ultra), an expansion of its pioneering ab interno canaloplasty platform. The new technology will be featured at this year's American Academy of Ophthalmology (AAO) annual meeting held on October 9-12 in New Orleans, Louisiana.

Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting

Sight Sciences, Inc. (SGHT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Sight Sciences, Inc. (SGHT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Sight Sciences, Inc. (SGHT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15

MENLO PARK, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15

TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

MENLO PARK, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies intended to transform care and improve patients' lives, today announced that, effective August 18, 2026, the U.S. Food and Drug Administration (FDA) updated the TearCare® System (TearCare) Indications for Use to state:

TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript

Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript

Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript

Sight Sciences Q2 Earnings Call Highlights

Sight Sciences NASDAQ: SGHT reported second-quarter revenue growth of 20% year over year, supported by gains in its interventional glaucoma and interventional dry eye businesses, while reducing operating expenses and cash usage. The company raised its full-year revenue outlook and lowered its adjusted operating expense guidance.

Sight Sciences Q2 Earnings Call Highlights

Zacks Investment Research

Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates

Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.23 per share a year ago.

Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research

Sight Sciences (SGHT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Sight Sciences (SGHT) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Sight Sciences (SGHT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.